Ratiopharm Acquisition Catapults Teva to Lead European Generics Market
PharmaDeals Analyst
Abstract
Teva Pharmaceutical Industries succeeded in finally buying Ratiopharm, Germany’s second largest generics producer from the beleaguered Merckle Group. The deal, valued at USD 4.95 B, places Teva as the top generics company in Europe.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.